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Say-Barber-Biesecker-Young-Simpson syndrome (SBBYSS or Ohdo syndrome) is a multiple anomaly syndrome characterized by severe
intellectual disability, blepharophimosis, and a mask-like facial appearance. A number of individuals with SBBYSS also have thyroid
abnormalities and cleft palate. The condition usually occurs sporadically and is therefore presumed to be due inmost cases to new domi-
nant mutations. In individuals with SBBYSS, a whole-exome sequencing approach was used to demonstrate de novo protein-truncating
mutations in the highly conserved histone acetyltransferase gene KAT6B (MYST4/MORF)) in three out of four individuals sequenced.
Sanger sequencing was used to confirm truncating mutations of KAT6B, clustering in the final exon of the gene in all four individuals
and in a further nine persons with typical SBBYSS. Where parental samples were available, the mutations were shown to have occurred
de novo. During mammalian development KAT6B is upregulated specifically in the developing central nervous system, facial structures,
and limb buds. The phenotypic features seen in the Qkf mouse, a hypomorphic Kat6bmutant, include small eyes, ventrally placed ears
and long first digits that mirror the human phenotype. This is a further example of how perturbation of a protein involved in chromatin
modification might give rise to a multisystem developmental disorder.Blepharophimosis, an abnormal narrowingof thepalpebral
fissures, is seen in association with intellectual disability
in the group of disorders collectively known as the blephar-
ophimosis-mental retardation syndromes.1 Although the
first of these was described by Ohdo et al.2 [MIM 249620],
the most distinctive phenotype is the Say-Barber-Bie-
secker-Young-Simpson syndrome (SBBYSS),3–5 which is
characterized by a distinctive facial appearance with severe
blepharophimosis, an immobile mask-like face, a bulbous
nasal tip, and a small mouth with a thin upper lip. (Fig-
ure 1A). The condition presents in infancy with severe
hypotonia and feeding problems. Associated skeletal prob-
lems include joint laxity, abnormally long thumbs and
great toes, and dislocated or hypoplastic patellae. Structural
cardiac defects are present in around 50% of cases, and
dental anomalies, including small and pointed teeth, are
common. Many affected individuals have abnormalities
of thyroid structure or function.5 SBBYSS is usually associ-
ated with severe mental retardation, delayed motor mile-
stones, and significantly impaired speech. The majority of
individuals with SBBYSS are simplex cases. Microarray
analyses of a previously reported clinical cohort6 failed to
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The Americantypical SBBYSS, and it was postulated that this condition
was most likely due to new dominant mutations within
a single gene. Here, we demonstrate that de novo protein-
truncating mutations within KAT6B [MIM 605880] on
chromosomal region 10q22, which encodes a highly
conserved histone acetyltransferase involved in chromatin
modification,7 give rise to the SBBYSS phenotype.
A cohort of 19 individuals with a presumed diagnosis of
SBBYSS were referred to an ethically approved research
study. Informed consent was obtained from each family
and clinical evaluation and genetic testing were carried
out in accordance with the ethics approval granted (04/
MRE10/1). Four of the families were approached to partic-
ipate in an extension study involving whole-exome
sequencing (MREC 10/H1016/12) and informed consent
was again obtained. On clinical evaluation, 12 individuals
were considered to have typical features of SBBYSS
syndrome, two had suggestive but milder features, and
five were classified as atypical. The clinical features of
each person are documented in detail in Table S1, available
online.
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Figure 1. Clinical Phenotype, Structure, and Truncating Mutation of KAT6B
(A) Photos showing clinical features of individual 10 with typical SBBYSS. Facial features include severe blepharophimosis, a bulbous
nasal tip, and a mask-like appearance. The thumbs and great toes are abnormally long and straight.
(B) Sanger sequencing of KAT6B in individual 4. The c.4069G>T (p.Glu1357X) mutation was absent in both parents and had arisen
de novo.
(C) Schematic of KAT6B including the conserved domains and position of truncating mutations. The catalytic MYST domain of the
MOZ-SAS family is the histoneacetyltransferase domain and contains a specific C2HC zinc finger together with an acetyl-coenzyme A
binding domain. There is a conserved N-terminal domain ([NEMM] the N-terminal domain conserved in Enok) and a highly conserved
C-terminal SM-rich domain. Mutations in typical SBBYSS individuals cluster in exon 18, the final exon, and leave the catalytic domain
intact.
(D) KAT6B isoforms. Alternative splicing of KAT6B produces five protein coding transcripts. Three transcripts vary only in the 50 UTR and
produce the samemature protein. In-frame splicing within exon 8 results in three protein isoforms of 1781, 1890, and 2013 amino acids
in length. As amino acid composition before and after exon 8 is identical in each isoform, the mutations found in exons 15 and 18 are
assumed to have the same effect.White boxes indicate exons in UTR; blue boxes indicate translated exons; red box indicates exon 8; blue
lines indicate introns. Mature protein contributed by exon 8 is shown in red; values indicate amino acid positions.
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Table 1. Filtering Procedure for Bioinformatics Analysis
Filtering for
Minimum 203
Novel Allele Depth
Total
SNVa
Variants not
in dbSNP132b
Total
Nonsynonymous
and Splice-Site SNV
Nonsynonymous
and Splice-Site SNV
not in dbSNP132c
Nonsense SNV
not in dbSNP132
Nonsense SNV
not in dbSNP132
Indels not in
dbSNP132
Person 1 29972 7478 8755 3533 174 0 1d
Person 2 28883 6775 8331 3229 136 1 1d
Person 3 29061 6806 8286 3119 143 0 0
Person 4 31467 7000 8828 3224 148 1d 0
The total number of SNVs seen in each individual is shown in column 1. Of the nonsynonymous and splice-site variants, those not in dbSNP132 were identified.
Filtering for genes where either nonsense variants or small indels were shared by the individuals studied revealed that three individuals had either a nonsense
variant or a small indel predicted to cause protein truncation in the KAT6B gene.
a SNV.
b SNP database.
c Unless seen in Human Gene Mutation Database.
d In KAT6B.Assay following themanufacturer’s protocol.Copy-number
data processing and visualization were performed with
Affymetrix Genotyping Console (version 3.0.1) set at a
50 kb threshold for genomic segment size with aminimum
of 25 markers per segment. External resources included
the Database of Genomic Variants, Ensembl, and Online
Mendelian Inheritance in Man. Seven out of nine individ-
uals (numbered 1, 2, 4, 5, 6, 10, and 14) had a normal
array result. Individual 3 was shown to have a de novo
duplication of approximately 2 Mb within the long arm of
chromosome 1 at band q21.1 (Figure S1A), similar to the
recurrent duplications of this region reported by Mefford
et al.8 Because this duplication is usually associated with
a very mild clinical phenotype, it was not considered
to be the cause of the severe SBBYSS phenotype in this
individual. Individual 17 had two significant imbalances
of chromosome 1, a deletion of ~8.3 Mb (1p36.12 to
1p36.21 nucleotides chromosome 1: 13339380-21692325
based on Ensembl Build 36) and a duplication of ~1.3 Mb
(1p34, nucleotides chromosome 1: 34572912-35949096,
Figures S1B and S1C). Although maternal fluorescence
in situhybridization studieswere normal, a paternal sample
was not available, and a de novo origin could not be
confirmed.
For exome sequencing, targeted enrichment and se-
quencing were performed on DNA extracted from the
peripheral blood of individuals 1, 2, 3, and 4, all of
whom were considered to have typical features of SBBYSS.
Enrichment was performed with SureSelect Human All
Exon 50MB Kit (Agilent), and the four samples were run
indexed on a SOLiD 4 sequencer (Life Technologies). Reads
were aligned to the human reference genome sequence
(USCS hg19 February 2009 Genome Reference Consortium
GRCh37). Bioinformatic analysis of results obtained is
summarized in Table 1. Assuming a de novo mutation
model, we filtered for variants on the same gene across
multiple individuals. This identified eight single nucleo-
tide variants (SNVs) of which only two were nonsense
mutations. Individual 4 had a heterozygous c.4069G>T
(p.Glu1357X) variant in KAT6B (RefSeq NM_012330.2).The AmericanTwo heterozygous indels (a 1 bp insertion and a 2 bp dele-
tion) were found in the same gene in individuals 1 and 2,
respectively. All three variants were confirmed with Sanger
sequencing. The c.4069G>T mutation was absent in both
parents and had arisen de novo (Figure 1B).
Subsequently, all 19 individuals with a SBBYSS or a
SBBYSS-like phenotype were sequenced for the entire
KAT6B coding region by classical Sanger sequencing.
Details of primer sequences are included in the supple-
mental information and PCR methods are available on
request. Results are shown in Table 2. Truncating muta-
tions were confirmed in 13 individuals, including indi-
vidual 3 who had a heterozygous frameshift mutation,
c.3018del (p.Glu1007ArgfsX5) in exon 15, not initially
detected on whole-exome sequencing. Individual 14,
who had amilder phenotype with less severe facial features
and milder intellectual disability, had a missense variant,
c.1078G>A (p.Glu360Lys) in exon 8. His parents were
not available for study. This same missense mutation was
subsequently identified in a normal control and was there-
fore deemed to be nonpathogenic. None of the other
variants were found in dbSNP132 or in 401 exomes of
the ClinSeq cohort9 of healthy individuals recruited to
a pilot study of exome sequencing (Table 3).
Mice carrying a gene trap insertion in the mouse ortho-
log Kat6b (Qkf/Myst4/Morf) that produces approximately
5% of the normal amount of Kat6b mRNA10 were exam-
ined for phenotypic characteristics seen in SBBYSS. All
experiments in mice were carried out according to the
Australian National Health and Medical Research Council
(NHMRC) code of conduct and approval of the Melbourne
Health Animal Ethics Committee. The Qkf gt/gt hypomor-
phic mutant displayed a number of defects that mirror
SBBYS syndrome, though the phenotype in the mice is
milder. Mice are of normal size at birth but fail to thrive
and have brain developmental defects as well as craniofa-
cial defects.11 Observed abnormalities include short and
narrow palpebral fissures, low set ears (Figures 2A and
2B), and malocclusion. Qkf mRNA is strongly expressed
in the eyelids and teeth primordia during development.Journal of Human Genetics 89, 675–681, November 11, 2011 677
Table 2. KAT6B Sequence Variants in 19 Individuals Tested
Individual Mutation Exon Parents Comments
1 NM_012330.2(KAT6B):c.4405dup (p.Ser1469Phefs*18) 18 not tested typical; case 322
2 NM_012330.2(KAT6B):c.5370_5373dup (p.Ile1792GlnfsX12) 18 not tested typical
3 NM_012330.2(KAT6B):c.3018del (p.Glu1007Argfs*5) 15 negative typical; also has 1q21.1 microdup
4 NM_012330.2(KAT6B):c.4069G>T (p.Glu1357*) 18 negative typical. Figure 3 in Day et al.6
5 NM_012330.2(KAT6B):c.4205_4206del (p.Ser1402Cysfs*5) 18 negative typical
6 NM_012330.2(KAT6B):c.5734A>T (p.Arg1912*) 18 not tested typical case 222
7 NM_012330.2(KAT6B):c.5030del (p.Thr1677Metfs*38) 18 not tested typical
8 NM_012330.2(KAT6B):c.5201_5210dup (p.Gln1737Hisfs*41) 18 not tested typical
9 NM_012330.2(KAT6B):c.5201_5210dup (p.Gln1737Hisfs*41) 18 negative typical
10 NM_012330.2(KAT6B):c.4205_4206del (p.Ser1402Cysfs*5) 18 not tested typical case 422
11 NM_012330.2(KAT6B):c.527dup (p.Tyr176*) 3 not tested SBBYSS-like, not typical
12 NM_012330.2(KAT6B):c.4911_4921del (p.Val1638Alafs*27) 18 negative typical
13 NM_012330.2(KAT6B):c.5389C>T (p.Arg1797*) 18 negative typical
14 NM_012330.2(KAT6B):c.1078G>A (p.Glu360Lys) 8 not tested milder phenotype
15 negative atypical
16 negative atypical
17 negative atypical; has 1p36 microdeletion
18 negative atypical
19 negative atypical
This table shows the Sanger sequencing results from the cohort of individuals tested. Individuals 1–4 are those where exome sequencing was carried out. Twelve of
the individuals were judged to have a typical clinical presentation, and sequence variants predicted to cause protein truncation were identified in all of these.
Eleven of these twelve variants were in exon 18. In addition, a truncating mutation was identified in exon 3 in a less typical individual and a missense variant
was identified in exon 8 in an individual with a much milder phenotype. This boy had only a moderate learning disability and significantly less speech delay.
This missense variant has subsequently been identified in a normal control and is now considered to be unrelated to the clinical presentation. The chance of finding
a KAT6B mutation in our series of clinically typical individuals was therefore high.(Figures 2C and 2D) Moreover, b-galactosidase expressed
from a lacZ reporter gene inserted into the Kat6b locus in
the Qkf gt allele, which reflects the high-level expression
domain of the Qkf locus, indicates that Qkf is activated
in the medial aspect of the hand and footplate at embry-
onic day 10 in the mouse and marks all digits as they arise
(Figure 2E). Similar to individuals with SBBYSS, the Qkf gt/gt
mice have long, slender feet and disproportionally long
first digits (Figure 2F). The thyroid gland in neonatal Qkf
mice is morphologically and histologically normal, though
the possibility of a functional defect of the thyroid has not
been explored.
Clinical diagnosis of blepharophimosis-learning dis-
ability syndromes is challenging. Autosomal-recessive,
autosomal-dominant, and X-linked inheritance have all
been proposed,1 making risk assessment for future preg-
nancies difficult. Our findings of KAT6B mutations in all
individuals with typical features of SBBYSS suggest that
this particular phenotype is a homogeneous disorder and
underlines the overlap between the phenotypes described
by Say and Barber,3 Biesecker,4 and Young and Simpson5
(YSS [MIM 603736]); the latter authors emphasize the addi-
tional features of polydactyly and thyroid abnormalities.678 The American Journal of Human Genetics 89, 675–681, NovembOur data suggest that the likelihood of identifying a
pathogenic KAT6B mutation in individuals with the
typical SBBYSS phenotype is high. Where the presentation
is atypical, the phenotype might have a separate genetic
etiology as evidenced by the likely pathogenic microarray
abnormality in Individual 17. We consider the 1q21 dupli-
cation in Individual 3 to be a coincidental occurrence.
The MYST proteins including KAT6B are the largest
group of histone acetyltransferases.7 Studies of the hypo-
morphic Qkf gt/gt mutant have demonstrated that Kat6b
is upregulated in developing cerebral cortex. It is also ex-
pressed in adult neural stem cells, osteoblasts, and germ
cells.11,12 Structural brain abnormalities have not been
studied extensively in individuals with SBBYSS, although
two individuals have been documented to have abnormal-
ities of the corpus callosum,6 and white matter changes
and delayed myelination have also been observed.13
Individuals with deletions of 10q22 involving KAT6B are
rare. Tzschach et al.14 reported three individuals with dele-
tions encompassing KAT6B, and all had a severe learning
disability. Their facial features were not, however, typical
of SBBYSS. Translocations through intron 16 of KAT6B
have been implicated in acute myeloid leukemia15 whereer 11, 2011
Table 3. Variants in KAT6B NM_12330 from the ClinSeq Cohort
Chromosome Start End Human Genome Variation Society Type of Variant RS
Homozygous
Frequency
Heterozygous
Frequency
10 76784992 76784993 c.3649G>T (p.Ala1217Ser) nonsynonymous rs57372986 0.9975 0.0025
10 76781027 76781028 c.3005G>A (p.Arg1002Gln) nonsynonymous – 0.9975 0.0025
10 76781906 76781930 c.3289_3291del3 DIV-c rs111976843 0.7292 0.2708
10 76789968 76789969 c.5386G>A (p.Glu1796Lys) nonsynonymous – 0.9975 0.0025
10 76789304 76789305 c.4722C>G (p.Asn1574Lys) nonsynonymous – 0.9975 0.0025
10 76784747 76784748 c.3404G>A (p.Arg1135His) nonsynonymous – 0.9975 0.0025
10 76789417 76789418 c.4835G>A (p.His1612Arg) nonsynonymous rs72803461 0.9925 0.0075
10 76735369 76735379 c.1274_1279del (p.Lys426_Val427del) DIV-c – 0.9975 0.0025
10 76735563 76735564 c.1469C>T (p.Pro490Leu) nonsynonymous – 0.995 0.005
10 76781875 76781876 c.3258A>C (p.Glu1086Asp) nonsynonymous – 0.9973 0.0027
10 76789092 76789093 c.4510G>A (p.Glu1504Lys) nonsynonymous – 0.9975 0.0025
10 76790184 76790185 c.5602G>A (p.Val1868Ile) nonsynonymous – 0.9975 0.0025
10 76789077 76789078 c.4495G>A (p.Val1499Ile) nonsynonymous rs3740321 0.9551 0.0424
10 76790331 76790332 c.5749A>G (p.Ile1917Val) nonsynonymous – 0.9975 0.0025the gene forms a fusion protein with Creb-binding protein.
Another translocation between the C terminus of KAT6B
and KAT2A (GCN5L2) [MIM 602301] occurs in benign
uterine leiomyomata.16 So far, no one with the SBBYSS
has developed a malignancy or uterine leiomyomata, but
follow-up into adulthood has been limited.
KAT6B has a highly conserved C-terminal serine and
methionine (SM)-rich domain encompassing exon 18
where the KAT6B mutations causing typical SBBYSS
cluster. This C-terminal region is known to bind to the
transcription factor RUNX2 (CBFA1) [MIM 600211]
in vitro and in vivo.17 Heterozygous loss-of-functionmuta-
tions of RUNX2 have been shown to cause cleidocranial
dysplasia (CCD [MIM 119600]), a disorder of membranous
bone ossification that affects the skull and clavicles.
Endogenous KAT6B is required for RUNX2-dependent tran-
scriptional activation.
Recently, a boy diagnosed with a phenotype that over-
lapped with Noonan syndrome (NS1 [MIM 163950]) was
reported to be haploinsufficient for KAT6B as a result of
a de novo t(10;13)(q22.3;q34) translocation with a break-
point in intron 3.18 This individual shared some clinical
features with those we have described who have heterozy-
gous point mutations and SBBYSS, including a learning
disability, blepharophimosis, ptosis, and ear anomalies;
however, the facial characteristics of the typical SBBYSS
individuals are more distinctive than his are. In this regard,
the Qkf gt mice more closely resemble the milder pheno-
type that overlaps with Noonan syndrome than the
SBBYSS phenotype associated with heterozygous point
mutations. These observations suggest that mutations of
protein-protein interaction domains in exon 18 result in
a more complex phenotype that is not due to simple hap-
loinsufficiency of KAT6B and raises the possibility thatThe Americanexon 18mutations are activating or have a dominant nega-
tive effect. Alternatively, haploinsufficiency for just a single
important domain could be responsible for the phenotype.
This situation is somewhat analogous to that seen in
Hajdu-Cheney syndrome (HJCYS [MIM 102500]), where
truncating mutations are confined to the C-terminal
region of NOTCH219 [MIM 600275] that contains a
proline-glutamate-serine-threonine-rich region important
in proteolytic recognition. If this region is missing,
NOTCH-2 signaling is increased. One argument against
this hypothesis might be the finding of an exon 15 muta-
tion in individual 3. However, assessing this child clini-
cally was difficult because she also has a copy number
variation at chromosomal region 1q21.1 that is likely to
have also contributed to her phenotype, and it is possible
that this exon 15 variant would produce a milder pheno-
type in the absence of the 1q21.1 duplication.
The finding of de novo KAT6B mutations in individuals
with the SBBYS phenotype confirms the condition as
a distinct clinical entity. Although the possibility of
gonadal mosaicism must be considered, and most likely
explains the rare familial recurrence of the condition,6
other individuals with SBBYSS are simplex cases, and unaf-
fected parents who do not carry the same mutation can
now be counseled with some reassurance that the risk
of recurrence is low, likely to be 1% or less on the basis
of clinical observations. This observation confirms the
important role of chromatin modifying genes in human
development.Supplemental Data
Supplemental Data include two figures and two tables and can be
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Figure 2. Morphology of Qkf gt/gt Mutant Mice and Expression of Kat6b mRNA in Tissues Affected in SBBYSS Individuals
(A) Facial features including small eyes and upturned nose in a 10-month-old male Qkf gt/gt mutant mouse compared to a same-sex wild-
type littermate control.
(B) External appearance of a 3-week-old male Qkf gt/gt mutant mouse and a male littermate control.
(C) Qkf mRNA distribution in E15.5 eyes and eyelids. Precipitated silver grains representing Qkf mRNA appear white in the darkfield
image; the brightfield image is in the adjacent panel.
(D) Qkf mRNA distribution in E15.5 tooth primordia.
(E) b-galactosidase reporter staining (blue) indicates high-expression activity of the Qkf locus in the developing hindlimb at the stages
indicated.
(F) Feet of a 3-week-old male Qkf gt/gt mutant mouse and a male littermate control. Note the long and slender appearance of the Qkf gt/gt
foot and digits. The following abbreviations are used: I to V, digits I to V of the hindlimb; EL, eyelids; Le, lens; To, tongue; TP, tooth
primordium; Re, retina. The scale bars (C and D) equal 133 mm. Embryo recovery, histological processing and sectioning, radioactive
in situ hybridization, and b-galactosidase staining were performed as previously published.10,20,21Acknowledgments
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